With support from a Wellcome Trust Seeding Drug Discovery award, the team has identified a preclinical candidate that they hope to take into human trials within a year.
Many people find they become more forgetful as they get older and we generally accept it as a natural part of the ageing process. Absent mindedness and a difficulty to concentrate are not uncommon, it takes longer to recall a person’s name, and we can’t remember where we left the car keys. These can all be early signs of the onset of dementia, but for most of us it’s just part of getting old.
Such memory loss has been linked with high levels of ‘stress’ steroid hormones known as glucocorticoids which have a deleterious effect on the part of the brain that helps us to remember. An enzyme called 11beta-HSD1 is involved in making these hormones and has been shown to be more active in the brain during ageing.
In a study published today in the ‘Journal of Neuroscience’, the team reports the effects of a new synthetic compound that selectively blocks 11beta-HSD1 on the ability of mice to complete a memory task, called the Y maze.
Professor Jonathan Seckl from the University of Edinburgh, who discovered the role of 11beta-HSD1 in the brain, described the findings: “Normal old mice often have marked deficits in learning and memory just like some elderly people. We found that life-long partial deficiency of 11beta-HSD1 prevented memory decline with ageing. But we were very surprised to find that the blocking compound works quickly over a few days to improve memory in old mice suggesting it might be a good treatment for the already elderly.”
The effects were seen after only ten days of treatment.
Professor Brian Walker and Dr Scott Webster from the University of Edinburgh are leading the drug development programme. Professor Walker added: “These results provide proof-of-concept that this class of drugs could be useful to treat age-related decline in memory. We previously showed that carbenoxolone, an old drug that blocks multiple enzymes including 11beta-HSD1, improves memory in healthy elderly men and in patients with type 2 diabetes after just a month of treatment, so we are optimistic that our new compounds will be effective in humans. The next step is to conduct further studies with our preclinical candidate to prove that the compound is safe to take into clinical trials, hopefully within a year.”
The 11beta-HSD1 enzyme has also been implicated in metabolic diseases including diabetes and obesity by the Edinburgh team, and similar drugs that block its activity outside of the brain are already under investigation.
This study was supported by the Wellcome Trust and the Medical Research Council (MRC). The drug development programme in Edinburgh is supported by a Seeding Drug Discovery award from the Wellcome Trust.
Dr Rick Davis of the Wellcome Trust commented: “Developing drugs that can selectively inhibit this enzyme has been a challenge to the pharmaceutical industry for nearly ten years. Advancing this compound towards clinical trials takes us a step closer to finding a drug that could have far reaching implications as the population ages.”
T 020 7611 7262
M 07534 143849
E [email protected]
Notes to editors
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
The University of Edinburgh‘s College of Medicine and Veterinary Medicine, top-rated for clinical medical and veterinary research in the UK Government’s Research Assessment Exercise, has a major interest in translating its leading science into health and wealth gain for the community based around the BioQuarter initiative supported by Scottish Enterprise.
For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century.
Karen Sooy et al. Partial deficiency or short-term inhibition of 11beta-Hydroxysteroid Dehydrogenase type 1 improves cognitive function in aging mice. Journal of Neuroscience, October 2010. [Epub ahead of print].